Surgical resection in the management of small-cell carcinoma of the lung.
Surgery has had little impact on long-term survival in patients with small-cell lung cancer (SCLC). With the evolution of modern techniques, however, surgery may play an increasingly valuable role in SCLC. Surgery may potentially cure a select minority of SCLC patients. Patients with peripheral nodules and those with regional disease achieving a complete response to chemotherapy may benefit from adjuvant surgical resection for removal of residual disease. In some cases, surgery may also be preferred over adjuvant radiotherapy, since the latter necessitates lowering the total chemotherapy dose administered to SCLC patients.
Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston.
S J
SJ
Mentzer
J J
JJ
Reilly
D J
DJ
Sugarbaker
D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging